Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › KTTA

Pasithea Therapeutics

KTTA Rare disease Lead: Phase 1 4 Biotech Distilled articles ↓ 20 filings & releases ↓ Cash $45.7M (Jun 30, 2026) ↓ 4 verdicts ↓
NeurologyOncology Small Molecule

Market cap $19.3M 33.4M shares (10-Q, Aug 12, 2026) × $0.579 close Nov 6, 2026

Most recent annual filing: 2026-03-30

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. PAS-004 Ph1 toplineNov 12–14, 2026PAS-004 Ph1 topline, Nov 12–14, 2026, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Discontinued (1)

Capital (as filed)

Cash
$45.7M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$4.7M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$50.4M cash, runway 1H 2028 per the update of Nov 3, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on Pasithea Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-05-16 Buy core Pasithea Therapeutics (KTTA) - Scientific Deep Dive for PAS-004 and Pipeline Products PAS-004's macrocyclic chemistry delivers a flat PK profile and zero DLTs through 45mg, creating a clean event-driven setup into Q2 and 2H 2026 NF1-PN readouts with a dilution-proof balance sheet.
  2. 2026-06-16 Buy core UPDATE: Pasithea Therapeutics (KTTA) - The Protocol Amendment Tax Protocol amendment delays the clean binary catalyst and widens dose-finding, but the macrocycle science is intact, the balance sheet is unchanged, and the 34.6% drawdown reflects timing re-pricing rather than thesis breakage.
  3. 2026-06-30 Buy core UPDATE: Pasithea Therapeutics (KTTA) - The Macrocycle Earns Its Keep Cancer cohort interim confirms durable disease control in BRAF/MEK-pretreated patients with zero DLTs, linear PK, and trough levels above IC50 at all doses, substantially de-risking the macrocycle's chronic tolerability pitch ahead of the Q4 NF1 interim.
  4. 2026-11-04 Buy core UPDATE: Pasithea Therapeutics (KTTA) - The Second Front Opens FDA IND clearance for a randomized placebo-controlled Phase 2 in NF1-cNF opens a second indication with no approved systemic competitor, enhancing M&A appeal, though no new efficacy data and unresolved runway guidance prevent an upgrade.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (20)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 2, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)